Literature DB >> 22592187

Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia.

John T Daugirdas1, Angelito A Bernardo.   

Abstract

Substantial activation of platelets can occur in the course of hemodialysis. Platelet surface markers show evidence of platelet degranulation. Some activation occurs due to exposure of blood to the roller pump segment and microbubbles may play a role. Platelet activation seems to be reduced with reused dialyzers or with those containing synthetic versus cellulosic membranes. Nevertheless, a substantial degree of platelet activation can be demonstrated with polysulfone and other synthetic membranes; the amount of activation may differ substantially among polysulfone membranes, depending on the manufacturer and the polyvinylpyrrolidone content. Platelet-platelet and platelet-leukocyte aggregates have been detected in the dialyzer blood outflow line and the consequences of these to the microcirculation are unknown. Typically, the platelet count decreases slightly during the first hour of dialysis, but mostly returns to initial values by the end of dialysis. A number of chronic hemodialysis patient cases have been reported in which a marked decrease in platelet count (50% or more) during dialysis was observed, resulting in mild degrees of predialysis thrombocytopenia. In only one case was the decrease in platelet count associated with bleeding. Dialyzer hypersensitivity symptoms are infrequently associated with a fall in platelet count. Most recent cases of dialysis-associated thrombocytopenia have been with polysulfone membranes, especially polysulfone membranes sterilized by electron beam. The exact cause of these reactions remains unknown.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592187     DOI: 10.1038/ki.2012.130

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  44 in total

Review 1.  Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose.

Authors:  John T Daugirdas
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

Review 2.  Twice-Weekly Hemodialysis in China: Can It Be A Better Option for Initiation or Maintenance Dialysis Therapy?

Authors:  Yucheng Yan; Sylvia Ramirez; Shuchi Anand; Jiaqi Qian; Li Zuo
Journal:  Semin Dial       Date:  2017-03-26       Impact factor: 3.455

3.  Platelet reactivity in patients with chronic kidney disease and hemodialysis.

Authors:  Philipp Mourikis; Carolin Helten; Lisa Dannenberg; Thomas Hohlfeld; Johannes Stegbauer; Tobias Petzold; Bodo Levkau; Tobias Zeus; Malte Kelm; Amin Polzin
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

4.  Effects of Baseline Thrombocytopenia and Platelet Decrease Following Renal Replacement Therapy Initiation in Patients With Severe Acute Kidney Injury.

Authors:  Benjamin R Griffin; Anna Jovanovich; Zhiying You; Paul Palevsky; Sarah Faubel; Diana Jalal
Journal:  Crit Care Med       Date:  2019-04       Impact factor: 7.598

Review 5.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

6.  Preliminary Diffusive Clearance of Silicon Nanopore Membranes in a Parallel Plate Configuration for Renal Replacement Therapy.

Authors:  Steven Kim; James Heller; Zohora Iqbal; Rishi Kant; Eun Jung Kim; Jeremy Durack; Maythem Saeed; Loi Do; Steven Hetts; Mark Wilson; Paul Brakeman; William H Fissell; Shuvo Roy
Journal:  ASAIO J       Date:  2016 Mar-Apr       Impact factor: 2.872

7.  Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial.

Authors:  Michael V Rocco; John T Daugirdas; Tom Greene; Robert S Lockridge; Christopher Chan; Andreas Pierratos; Robert Lindsay; Brett Larive; Glenn M Chertow; Gerald J Beck; Paul W Eggers; Alan S Kliger
Journal:  Am J Kidney Dis       Date:  2015-04-08       Impact factor: 8.860

8.  Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure.

Authors:  Ryan McMillan; Leonidas Skiadopoulos; Debra Hoppensteadt; Nil Guler; Vinod Bansal; Ravipresenna Parasuraman; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-08       Impact factor: 2.389

9.  Ability of a novel system for neonatal extracorporeal renal replacement therapy with an ultra-small volume circuit to remove solutes in vitro.

Authors:  Saeko Nishimi; Ken Ishikawa; Makoto Sasaki; Hiromi Furukawa; Akira Takada; Shoichi Chida
Journal:  Pediatr Nephrol       Date:  2015-10-22       Impact factor: 3.714

10.  The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Authors:  Christina U Lorentz; Erik I Tucker; Norah G Verbout; Joseph J Shatzel; Sven R Olson; Brandon D Markway; Michael Wallisch; Martina Ralle; Monica T Hinds; Owen J T McCarty; David Gailani; Jeffrey I Weitz; András Gruber
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.